Small intestine cancer (small bowel adenocarcinoma)

What changed: Small intestine cancer (small bowel adenocarcinoma)

Cancer page →

Every dated change on the records linked to Small intestine cancer (small bowel adenocarcinoma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Guideline1Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordSmall intestine cancer (small bowel adenocarcinoma)
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 2

2019 · 1

2019MilestoneSmall intestine cancer (small bowel adenocarcinoma)
NCCN publishes dedicated SBA guideline
A milestone in how this cancer is treated.

2017 · 1

2017MilestonePembrolizumab
Pembrolizumab tumour-agnostic approval for MSI-high cancers
Small bowel adenocarcinoma is one of the eligible tumours.

2016 · 1

2016MilestoneSmall intestine cancer (small bowel adenocarcinoma)
BALLAD adjuvant trial opens
First randomised trial in resected small bowel adenocarcinoma (NCT02502370).

2015 · 1

2015MilestoneSmall intestine cancer (small bowel adenocarcinoma)
Molecular landscape of SBA published
Schrock and colleagues (JAMA Oncol 2017) later show SBA is genomically distinct from colorectal and gastric cancer, with frequent dMMR and ERBB2 alterations.

2005 · 1

2005MilestoneSmall intestine cancer (small bowel adenocarcinoma)
Systematic profiling of SBA begins
Registry analyses show the distinct site distribution and association with Crohn's, coeliac and FAP.